Merck has inaugurated a new state-of-the-art office for its Healthcare Research and Development (R&D) India Hub at Bagmane Solarium City in Whitefield, Bengaluru, marking a significant expansion of its R&D footprint in the country. The move reinforces India’s position as a strategic centre for Merck’s global healthcare innovation and scientific research.
The new facility, which replaces the company’s earlier R&D office at Electronic City Software Park, offers a substantially larger and thoughtfully designed workspace to support workforce expansion and advanced R&D activities. The office has been developed with a strong focus on collaboration, inclusivity, employee experience, and sustainability, featuring ergonomic workstations, smart technologies, and future-ready global design standards.
The expansion reflects Merck’s long-term commitment to India as a key hub for healthcare innovation, advanced research, and scientific excellence. India represents Merck’s fourth-largest global workforce base, following Germany, the United States, and China, and plays a critical role in supporting the company’s global Healthcare R&D strategy.
Established in 2022 as the Merck India R&D Excellence Centre, the Healthcare R&D India Hub has rapidly scaled both in headcount and capabilities. It now supports a wide range of global R&D functions, including Regulatory Affairs, R&D Quality and Risk Management, Regulatory Quality Operations, Drug Safety and Pharmacovigilance, Clinical Operations, and Portfolio Strategy and Management. The hub also serves as a Centre of Excellence for Scientific Communications, Medical Writing, Project Management, and Biostatistics.
Alongside the expanded Bengaluru headquarters, Merck continues to strengthen its R&D presence in India through a dedicated site in Hyderabad and operations in its Mumbai office.
The inauguration of the new Bengaluru facility is expected to drive further growth, collaboration, and sustained momentum across Merck’s global healthcare R&D activities.
